Data reporting adverse effects associated with mTOR inhibitor therapy and non-mTOR inhibitor therapy for the treatment of pediatric patients with TSC were published in 11 studies (n=129) (13–19,25–28). The gene discussed is MTOR; the disease is tuberous sclerosis.